眼内用药（Intraocular medication）.docVIP

眼内用药（Intraocular medication） Subject: Intraocular + = put away all the attention Brimonidine tartrate [pharmacological action] this drug is an eye with relatively selective alpha 2 adrenergic agonist effects on cardiovascular and pulmonary function is very small, two hours after treatment effect of lowering intraocular pressure peak in animal and human studies were measured by fluorescence spectrophotometry showed that brimonidine tartrate has dual action mechanism; both reduce aqueous humor production, and increase uveoscleral outflow. [pharmacokinetics] after dropping 0.2% of the drug solution into the eye, the plasma concentration peaked within 1-4 hours, then declined, about 3 hours, and the plasma concentration was halved. In the body, brimonidine is a major site of metabolism of liver metabolism. TC and its metabolites in urine, oral administration of radiolabeled Mooney bromide after, about 87% of the drug was removed within 120 hours, accounting for about 74% in urine. [indications] the utility model is suitable for reducing intraocular pressure of patients with open-angle glaucoma and ocular hypertension. [dosage] the recommended dosage of this medicine is once a day, one drop each time, drop into the eye. Patients whose intraocular pressure peaks in the afternoon or whose intraocular pressure needs to be controlled will be increased by one drop in the afternoon. About 10-30% [adverse reaction] people appear in descending order, the following adverse reactions including dry mouth, bloodshot eyes, burning and tingling, headache, blurred vision, eye discomfort, fatigue, conjunctival follicle, ocular allergic reaction and eye itching. This 3-9% appears the following adverse reactions, in descending order, including staining of cornea ulcer, drying, tears, symptoms of upper respiratory tract infections, eyelid edema, conjunctival edema, dizziness, blepharitis, eye irritation, gastrointestinal symptoms, weakness, conjunctival white, as abnormal and muscle pain.